The effect of hormone therapy on breast density following risk-reducing salpingo-oophorectomy in women with an increased risk for breast and ovarian cancer

Menopause. 2021 Aug 9;28(11):1307-1312. doi: 10.1097/GME.0000000000001844.

Abstract

Objective: To compare the effect of tibolone to conjugated estrogens with medroxyprogesterone-acetate (CEE + MPA) on breast density, as a predictor for breast cancer risk, in women with a high risk of breast and ovarian cancer.

Methods: Women aged 30-50 (N = 114) who had undergone risk-reducing salpingo-oophorectomy (RRSO) were randomized to tibolone or CEE + MPA.

Results: Breast density decreased 46% after RRSO in untreated women, 39% after treatment with tibolone, and 17% after treatment with CEE + MPA; the decrease in breast density after CEE + MPA was significantly different compared with that of untreated women (P = 0.017).

Conclusions: A decline in breast density is seen after premenopausal RRSO despite the use of both CEE + MPA or tibolone, although lower breast density is seen after tibolone use.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Breast Density*
  • Estrogen Replacement Therapy
  • Estrogens, Conjugated (USP)
  • Female
  • Humans
  • Medroxyprogesterone Acetate
  • Norpregnenes
  • Ovarian Neoplasms* / prevention & control
  • Salpingo-oophorectomy

Substances

  • Estrogens, Conjugated (USP)
  • Norpregnenes
  • Medroxyprogesterone Acetate

Associated data

  • NTR/NTR637